Background: Small lymphocytic lymphoma is a relatively rare B-cell non-Hodgkin lymphoma that is considered to be the tissue equivalent of the much more common entity chronic lymphocytic leukemia.

Small lymphocytic lymphoma (SLL), the tissue equivalent of ... and the presence of infiltrating monoclonal B cells having the same immunophenotype as CLL cells but lacking peripheral blood ...

or small lymphocytic lymphoma (SLL). Breyanzi is a CD19-directed chimeric antigen receptor (CAR)-T cell therapy designed to be administered intravenously as a one-time infusion to patients who ...

previously untreated diffuse large B-cell lymphoma and chronic lymphocytic leukaemia. In combination with other drugs, rituximab has become the standard of care for several types of non-Hodgkin ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

My work focuses on the development of novel therapies for patients with B cell lymphoma, including indolent lymphomas (follicular, marginal zone, small lymphocytic), Waldenström’s macroglobulinemia, ...

InnoCare Pharma has received clearance for an investigational new drug (IND) application to conduct a clinical trial of ICP-248 plus orelabrutinib in China for lymphocytic leukaemia (CLL)/small ...

The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...